Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal

NCT04939623

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Calgary
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (5)

- Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment.
- Subjects are currently taking a daily opioid pain medication and planning to taper the dose.
- Participants complete at least one voluntary opioid dose reduction in the twelve-week study period.
- Glomerular filtration rate (GFR) \> 50 mL/min
- Capable of providing informed consent

Exclusion (20)

- Allergy to probenecid or related drugs
- History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi.
- Known G6PD deficiency
- Active gout in any joint
- Current use of drugs whose exposure may be prolonged, or risk of toxicity increased when used in combination with probenecid:

... and 15 more (see full listing online)

Locations (1 total)

Richmond Road Diagnostic and Treatment Centre, Calgary, Alberta, Canada

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.